Contact Sales
.

The federal 340B drug pricing program, designed to provide significant savings for healthcare providers serving vulnerable populations, faces a potential shift from discount models to rebate systems, sparking ongoing debate. While manufacturers are attracted to rebates to ensure proper validation and address financial concerns, providers argue this change would impose higher costs and strain resources needed for patient care. The legality of the rebate model remains under scrutiny, with potential industry-wide implications, yet should it become a reality Model N is prepared to support this transition with its adaptable platform and partnering with other vendors.

What You’ll Learn 

  • Explore the impact of transitioning 340B from a discount to a rebate model.
  • Learn strategies to navigate regulatory, operational, and financial implications.
  • Discover how technology can streamline 340B rebate management and ensure compliance.

Featured Speakers

jesse-mendelsohn

Jesse Mendelsohn

SVP Professional Services,

Model N

dhirendra-jena-model-n

Dhirendra Jena

Sr. Director, Professional Services,

Model N